Poised for Success
Xequel Bio, a clinical stage biopharmaceutical company whose technology was licensed from the Medical University of South Carolina, is transforming its proprietary aCT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.
Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.
This is our Xequel. Get ready to watch an exciting story unfold.
Xequel’s proprietary aCT1 peptide technology platform has multiple unique applications and formulations across therapeutic areas.
110+ Preclinical Studies and 9 Clinical Trials
63 Issued Patents Globally
Private Equity Backed and $30M+ in NIH/DOD Research Funding
Proven Leadership Team with Deep R&D and Commercial Expertise
Jerry St. Peter
Chief Executive Officer and Director
30+ Years Experience
Wes Brazell
Chief Financial Officer
30+ Years Experience
Mike Brubaker, PhD
Chief Scientific Officer
25+ Years Experience
Linda Davis
Senior Director, Human Resources and Administration
25+ Years Experience
David Leffell, MD
Chief Medical Advisor
30+ Years Experience
Tony Tipton
Chief Operating Officer
25+ Years Experience
